Search results for " ratio"

showing 10 items of 3859 documents

Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (…

2016

Background: RES reduced exacerbation frequency and improved lung function and asthma control in pts with inadequately controlled asthma and elevated blood eosinophils (EOS) in two PBO-controlled, phase 3 trials (Castro et al. Lancet Resp Med 2015). Aims/objectives: To determine the efficacy of RES in asthma pts stratified by GINA Step 4 (G4) and Step 5 (G5) categories of asthma severity. Methods: Pooled data from two 52-week, PBO-controlled trials of RES (3mg/kg IV Q4W) in pts with inadequately controlled asthma and blood EOS ≥400/µL on inhaled corticosteroid (ICS) ± another controller; primary results have been reported. Current analysis includes pts stratified by G4 (medium/high-dose ICS …

medicine.medical_specialtyPediatricsExacerbationbusiness.industrymedicine.drug_classEosinophilic asthmaPlaceboRate ratiomedicine.diseaserespiratory tract diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemReslizumabInternal medicineAsthma controlMedicineCorticosteroid030212 general & internal medicinebusinessmedicine.drugAsthma5.1 Airway Pharmacology and Treatment
researchProduct

The course of psychiatric co-morbidity in patients with breast cancer - results from the prospective multi-centre BRENDA II study

2015

Purpose This study examined the frequency of psychiatric co-morbidity in patients with breast cancer, its changes over time and predictors for these changes. Methods In a prospective study with measurements before surgery (t1, baseline), 1 month (t2) and 8 months thereafter (t3) using the Patient Health Questionnaire, we examined the course of psychiatric co-morbidity in breast cancer patients. The co-morbidity courses were grouped into healthy (no co-morbidity during the study), acute (co-morbidity at t1 and/or t2, but not at t3), emerging (no co-morbidity at t1, but at t3) and chronic (co-morbidity at t1 and t3). Results Of the 598 participants, 19% had acute, 10% emerging and 9% chronic …

medicine.medical_specialtyPediatricsbusiness.industry05 social sciencesCancerExperimental and Cognitive PsychologyOdds ratio050108 psychoanalysismedicine.diseaseComorbidityConfidence intervalPatient Health Questionnaire03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineBreast cancerOncologyQuality of life030220 oncology & carcinogenesismental disordersmedicine0501 psychology and cognitive sciencesPsychiatrybusinessProspective cohort studyPsycho-Oncology
researchProduct

Hypothenar hammer syndrome: A multicenter case-control study

2013

Background The rarely diagnosed hypothenar hammer syndrome (HHS) is due to vascular damage to the distal part of the ulnar artery probably caused by acute or repetitive blunt trauma to the hypothenar region. To date, mainly case reports have been published, while epidemiological data are almost absent. Aim To identify potential risk factors for HHS. Method An interview-based multicenter case–control study of 71 patients with HHS and 105 matched controls was conducted with standardized questions regarding disease specific variables, occupation, exposure of the hands to different types of trauma in occupational and leisure context. Medical data were verified from individual medical records. R…

medicine.medical_specialtyPediatricsbusiness.industryMedical recordPublic Health Environmental and Occupational HealthCase-control studyContext (language use)Odds ratioLogistic regressionSurgeryBlunt traumaEpidemiologymedicineEtiologybusinessAmerican Journal of Industrial Medicine
researchProduct

Thrombin generation in cardiovascular disease and mortality – results from the Gutenberg Health Study

2020

Thrombin generation may be a potential tool to improve risk stratification for cardiovascular diseases. The aim of this study was to explore the relation between thrombin generation and cardiovascular risk factors, cardiovascular diseases, and total mortality. For this study, 5,000 subjects from the population-based Gutenberg Health Study were analyzed in a highly standardized setting. Thrombin generation was assessed by the Calibrated Automated Thrombogram method at 1 and 5 pM tissue factor triggers in platelet-poor plasma. Lag time, endogenous thrombin potential, and peak height were derived from the thrombin generation curve. Sex-specific multivariable linear regression analysis adjusted…

medicine.medical_specialtyPercentilePopulationDiseaseDETERMINANTS030204 cardiovascular system & hematologyFACTOR PATHWAY INHIBITORVALIDATIONArticle03 medical and health sciencesTissue factor0302 clinical medicineInternal medicineMedicineeducationPlatelet-poor plasmaeducation.field_of_studyCOAGULATION-FACTORSPLASMAbusiness.industryProportional hazards modelCALIBRATED AUTOMATED THROMBOGRAMHazard ratioORAL-CONTRACEPTIVESHematologymedicine.diseaseObesityTISSUE FACTOROBESITYATRIAL-FIBRILLATIONCardiologybusiness030215 immunologyHaematologica
researchProduct

Height as a potential indicator of early life events predicting Parkinson's disease: A case-control study

2007

Aim of this study was to investigate the relationship between height in young adult age and Parkinson's disease (PD) risk. We included 266 persons affected by idiopathic PD. Patients were matched by age and sex to 266 controls by a random selection from the municipality of residence. We collected information about height preceding PD from official documents where these characteristics referred to young adult age (nearly 30 years). We compared height in cases and controls by calculating differences in mean distribution and by χ2 analyses. Crude and adjusted odds ratios (OR) and 95% confidence intervals (CI) were calculated by logistic regression models. Mean height was significantly lower in…

medicine.medical_specialtyPercentilebusiness.industryCase-control studyOdds ratioLogistic regressionConfidence intervalSurgeryNeurologyEpidemiologymedicineNeurology (clinical)Risk factorYoung adultbusinessDemographyMovement Disorders
researchProduct

Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-…

2019

Abstract Aims ST-segment elevation myocardial infarction (STEMI) guidelines recommend primary percutaneous coronary intervention (pPCI) as the default reperfusion strategy when feasible ≤120 min of diagnostic ECG, and a pharmaco-invasive strategy otherwise. There is, however, a lack of direct evidence to support the guidelines, and in real-world situations, pPCI is often performed beyond recommended timelines. To assess 5-year outcomes according to timing of pPCI (timely vs. late) compared with a pharmaco-invasive strategy (fibrinolysis with referral to PCI centre). Methods and results The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme c…

medicine.medical_specialtyPercutaneousmedicine.medical_treatment[SDV]Life Sciences [q-bio]Myocardial InfarctionAcute myocardial infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineReperfusion therapyFibrinolytic Agents[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemFibrinolysismedicineHumansST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesTimingPrimary PCIbusiness.industryFibrinolysisHazard ratioPercutaneous coronary interventionmedicine.diseaseLong-term outcome3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV] Life Sciences [q-bio]Treatment OutcomeEmergency medicineConventional PCIST Elevation Myocardial InfarctionCardiology and Cardiovascular Medicinebusiness
researchProduct

Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma

2011

Abstract Abstract 2708 Background: The simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) has been shown to be a good predictor of patient survival (Blood 2008;111:558–65; Blood 2010;115:1530–1533). This post hoc study analyzed data from a randomized, phase III clinical trial investigating temsirolimus (TEM) in relapsed/refractory mantle cell lymphoma (MCL) in which TEM 175/75 (175 mg for first 3 weeks then 75 mg weekly) demonstrated significantly longer progression-free survival (PFS) vs investigator's choice of therapy (INV; 4.8 vs 1.9 months, respectively; hazard ratio [HR]=0.44; P=.0009; J Clin Oncol 2009;27:3822–9). Patients receiving TEM 175/25 (175 mg for first 3 w…

medicine.medical_specialtyPerformance statusAnemiabusiness.industryIncidence (epidemiology)ImmunologyHazard ratioCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyTemsirolimusInternational Prognostic IndexRenal cell carcinomaInternal medicinemedicineMantle cell lymphomabusinessmedicine.drugBlood
researchProduct

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic ha…

2021

BACKGROUND: Cytomegalovirus (CMV) is a complication of allogeneic haematopoietic cell transplantation (allo-HCT). ASP0113, a DNA-based vaccine, contains two plasmids encoding human CMV glycoprotein B and phosphoprotein 65 (pp65). We assessed ASP0113 in CMV-seropositive allo-HCT recipients. METHODS: In this phase 3, randomised, placebo-controlled study, CMV-seropositive allo-HCT recipients were randomly assigned (1:1) via interactive response technology to receive five injections of 1 mL of 5 mg/mL ASP0113 or placebo. The pharmacist and designated staff were unblinded. Masked syringes maintained the blind for patients and study personnel. Efficacy and safety analyses included patients who re…

medicine.medical_specialtyPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerDiseaseGANCICLOVIRPlacebo01 natural sciencesPROPHYLAXIS03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMedicine General & Internal[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneral & Internal MedicinemedicineCYTOMEGALOVIRUS DISEASE030212 general & internal medicine0101 mathematicsAdverse effectlcsh:R5-920Science & Technologybusiness.industryIncidence (epidemiology)010102 general mathematicsGeneral MedicineOdds ratioConfidence interval3. Good healthbusinessComplicationlcsh:Medicine (General)Life Sciences & BiomedicineResearch PaperEClinicalMedicine
researchProduct

The Association between Tooth Loss and Alzheimer's Disease: a Systematic Review with Meta-Analysis of Case Control Studies.

2019

Alzheimer’s disease is classified as a neurodegenerative condition, a heterogeneous group of illnesses characterized by the slow and progressive loss of one or more functions of the nervous system. Its incidence tends to increase gradually from 65 years of age, up to a prevalence of 4% at age 75. The loss of dental elements is more prevalent in this population and might negatively affect the masticatory capacity, quality of life, and pathogenesis of Alzheimer’s disease. This study investigated problems related to oral health and the loss of dental elements in elderly patients suffering from Alzheimer’s and considered whether local inflammatory processes could affect the et…

medicine.medical_specialtyPopulationDiseaseReview03 medical and health sciences0302 clinical medicineInternal medicinetooth lossTooth lossmedicineDementiaeducationGeneral DentistryperiodontitisPeriodontitiseducation.field_of_studyEdentulismbusiness.industryHazard ratioCase-control study030206 dentistrymedicine.diseaselcsh:RK1-715stomatognathic diseaseslcsh:Dentistrymedicine.symptombusinessAlzheimer’s disease030217 neurology & neurosurgerydementiaDentistry journal
researchProduct

Comparación de las frecuencias de los alelos factor V Leiden (G1691A) y protrombina-G20210A entre pacientes con trombosis venosa profunda y población…

2006

Background: Factor V leiden and the -G20210A variant of prothrombin gene are associated to a higher risk of deep venous thrombosis. Aim: To assess the frequency of factor V Leiden (G1691A) and prothrombin -G20210A alleles in patients with deep venous thrombosis (DVT) and in the general population from Spain. Material and methods: Factor V Leiden (g1691a) and prothrombin-g20210a alleles were genotyped in 493 individuals from the Spanish general populations and in 131 patients with DVT. The presence of DVT was confirmed by phlebography. Allelic frequencies and the DVT risk associated with these variants were estimated. Results: Allelic frequencies for the factor V Leiden (G1691A) allele were …

medicine.medical_specialtyPopulationGastroenterologyInternal medicinehemic and lymphatic diseasesGenotypeG20210AVenous thrombosismedicineFactor V Leidencardiovascular diseasesAlleleeducationAlleleseducation.field_of_studyFactor V Leidenbusiness.industryGeneral MedicineOdds ratiomedicine.diseaseConfidence intervalSurgeryVenous thrombosisProthrombin geneProthrombin G20210Abusiness
researchProduct